Funding for this research was provided by:
National Health and Medical Research Council (1085461, 1082910)
First Online: 18 June 2020
Compliance with Ethical Standards
: Adam Vogel is Chief Science Officer of Redenlab Inc. He receives grant and fellowship funding from the National Health and Medical Research Council of Australia. Andrew Evans received honoraria from Novartis for giving presentations and providing consultancy services. He has participated in scientific advisory board meetings for Novartis, UCB Pharma, Allergan, and Boehringer Ingelheim. He has received conference travel support from Boehringer Ingelheim. Anneke van der Walt has received travel support and served on advisory boards for Novartis, Biogen, Merck Serono, Roche and Teva. She receives grant support from the National Health and Medical Research Council of Australia. Frederique M.C. Boonstra has nothing to disclose. Gustavo Noffs has nothing to disclose. Helmut Butzkueven served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and received conference travel support from Novartis, Biogen and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen and Novartis received research support from Merck, Novartis and Biogen. Scott Kolbe receives grant income from the National Health and Medical Research Council of Australia and has received honoraria from Novartis, Biogen and Merck. Thushara Perera has nothing to disclose.